SPR-720 is a Small Molecule owned by Spero Therapeutics, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.
SPR-720 (VXc-486) acts through dual inhibition of GyrB and ParE enzymes. The bacterial enzyme, GyrB has ATP binding site responsible for cellular functioning. The bacterial topoisomerase IV enzyme is essential for chromosome segregation. It relaxes supercoiled DNA. It performs the decatenation events required during the replication of a circular DNA molecule.
The revenue for SPR-720 is expected to reach a total of $3.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the SPR-720 NPV Report.
SPR-720 (VXc-486) is under development for the prevention of tuberculosis. The drug candidate is administered orally in the form of capsule. It acts by targeting DNA gyrase B (GyrB) and topoisomerase IV (ParE). The drug candidate is a new molecular entity (NME). Phase II trial is registered for mycobacterium avium complex (MAC) pulmonary disease which is not yet open for recruitment.
It was under development for the treatment of pulmonary non-tuberculosis mycobacterium (Mycobacterium avium complex and Mycobacterium abscessus) infections.
Spero Therapeutics Overview
Spero Therapeutics. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 IV potentiator platform, and SPR720 non-tuberculosis mycobacterium. The company markets its products through third party distributors. Its partners include U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DoD) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Spero is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$18.3 million for the fiscal year ended December 2021 (FY2021), an increase of 95.7% over FY2020. The operating loss of the company was US$88 million in FY2021, compared to an operating loss of US$79.1 million in FY2020. The net loss of the company was US$89.8 million in FY2021, compared to a net loss of US$78.3 million in FY2020. The company reported revenues of US$2 million for the third quarter ended September 2022, an increase of 0.7% over the previous quarter.
Quick View – SPR-720
|Highest Development Stage|